華潤醫療(01515.HK)全年實現歸母淨利潤3.91億元 末期息10港仙
格隆匯3月24日丨華潤醫療(01515.HK)發佈全年業績，截至2019年12月31日止年度，公司實現收益21.1532億元(人民幣，下同)，同比增長2.71%；實現母公司擁有人應占年度利潤3.91億元，基本每股盈利0.31元，擬派末期股息每股10港仙。
報告期內，集團繼續加強對醫療機構的管理和增效能力，進一步完善集團化運營管理體系，提升精細化管理能力；建立學科運營體系，助力專科能力提升；建設患者服務體系，提升醫療服務品質；強化EHSQ體系(即“環境—健康—安全—質量”體系)管理，持續提升醫療品質降低風險；探索創新模式，實現集團化醫療+互聯網落地。得益於上述舉措，存量醫院的運營效率和盈利能力得到持續提升。
截至2019年12月31日，集團在中國10個省、市共管理運營107家醫療機構，集團旗下醫院門診量和住院量分別增長6.8%和1.7%至8,780,915人次和252,368人次，惟門診均次費用同比下降4.5%，住院均次費用較去年增長1.5%，集團旗下醫院的醫療業務總收入同比增長2.8%至約68.69億元。
分部業績方面，報告期內，集團全面實施提質增效策略，故存量醫院業績穩步提升，較有效抵銷了燕化IOT協議爭議帶來的不利影響；而2019年各業務分部利潤合計約為6.61億元，仍較上年同比增長約2.2%。如扣除兩個對比期間燕化醫院集團對集團的業績貢獻，2019年各業務分部利潤合計為6.57億元，上年為5.40億元，同比增長21.7%。
此外，集團旗下存量醫院在報告期內的業績表現較優，較好地減輕了燕化IOT協議爭議的影響，故2019年集團淨利潤為4.01億元，同比下降8.9%。如扣除於報告期及2018年燕化醫院對集團的税後業績貢獻，即分別為314萬元及7,984萬元，則集團2019年淨利潤為3.97億元(2018年：3.60億元)，同比增長10.5%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
